Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:34:57 EDT Tue 25 Mar 2025
Enter Symbol
or Name
USA
CA



Q:CAPR - CAPRICOR THERAPEUTICS INC - https://www.capricor.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CAPR - Q1.013.01·14.440.113.28+0.423.3804.010,0198,23113.125  13.32  12.639723.40  3.52Mar 24Mar 1915 min RT 2¢

Recent Trades - Last 10 of 8231
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-19 16:05U:CAPRNews ReleaseCapricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025-03-17 09:25U:CAPRNews ReleaseCapricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
2025-03-11 09:00U:CAPRNews ReleaseCapricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
2025-03-10 09:13U:CAPRNews ReleaseFDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
2025-03-07 09:25U:CAPRNews ReleaseCapricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025
2025-03-04 07:00U:CAPRNews ReleaseCapricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
2025-02-10 09:00U:CAPRNews ReleaseCapricor Therapeutics to Participate in Upcoming Investor Conferences
2025-01-02 09:15U:CAPRNews ReleaseCapricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
2024-12-02 16:15U:CAPRNews ReleaseCapricor Therapeutics to Present at Upcoming Investor Conferences
2024-11-20 09:00U:CAPRNews ReleaseCapricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
2024-11-13 16:01U:CAPRNews ReleaseCapricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-12 09:00U:CAPRNews ReleaseCapricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
2024-11-05 09:00U:CAPRNews ReleaseCapricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
2024-10-18 16:01U:CAPRNews ReleaseCapricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
2024-10-17 06:00U:CAPRNews ReleaseCapricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
2024-10-16 16:18U:CAPRNews ReleaseCapricor Therapeutics Announces Proposed Public Offering of Common Stock
2024-10-11 09:15U:CAPRNews ReleaseCapricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
2024-10-09 09:15U:CAPRNews ReleaseCapricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
2024-10-04 09:15U:CAPRNews ReleaseCapricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
2024-09-24 08:00U:CAPRNews ReleaseCapricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy